Navigation Links
Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL
Date:7/28/2008

NEW YORK, July 28 /PRNewswire/ -- Polyphenon Pharma, an emerging research-based pharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to its botanical drug, Polyphenon E(R), for the treatment of chronic lymphocytic leukemia (CLL). A Phase II study is currently underway at the Mayo Clinic in Rochester, Minnesota where researchers are studying the effects of an oral daily dose of Polyphenon E in CLL patients.

"The FDA Orphan Drug Designation for Polyphenon E represents a significant milestone in the development of this drug," said Stig Ogata, Polyphenon Pharma's Chief Operating Officer. "Orphan drug status provides incentives that can help accelerate the development process of Polyphenon E as an oral treatment for patients with CLL. This in turn could lead to other potential development opportunities for this drug in the area of oncology."

The FDA grants Orphan Drug Designation to encourage biotechnology and pharmaceutical companies to develop products that demonstrate promise for the treatment of rare diseases affecting fewer than 200,000 people in the United States. This designation will entitle Polyphenon Pharma to seven years of marketing exclusivity for the drug upon FDA approval.

Polyphenon E contains highly characterized catechins that are extracted from green tea leaves through a proprietary process. The primary catechin in Polyphenon E, epigallocatechin gallate (EGCG), has been shown to affect many processes in the body related to abnormal cellular activity that can lead to cancer. Preclinical studies indicate that the catechins present in Polyphenon E may have multiple methods of action.

About CLL

Chronic Lymphocytic Leukemia (CLL) is a type of cancer of the blood and bone marrow that progresses more slowly than acute leukemia. It affects a group of white blood cells called lymphocytes, which typically fight infection. Each year, about 10,000 people in
'/>"/>

SOURCE Polyphenon Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
2. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
3. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
4. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
5. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
6. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
7. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
8. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
9. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
10. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
11. Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
(Date:7/31/2014)... Lazarus Effect, a medical device company focused ... removal of blood clots, announced the closing of a ... EU commercialization of several approved Lazarus Effect devices, as ... Lazarus Cover™ in the United States ... the value of our novel, platform technology as well ...
(Date:7/31/2014)... , July 31, 2014 For its innovative ... California , Art,s-Way Scientific has earned a Modular ... With competition in over 30 categories, MBI,s contest is ... members, which include building manufacturers, dealers, and product and ... excellent example the capability of our team," said ...
Breaking Medicine Technology:Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Lazarus Effect Closes $5 Million Financing 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
... Oct. 1 Health Strategies Group, a leading ... industries, has just launched Oncology Performance Edge, a new ... in the oncology field improve brand performance by understanding ... oncology market is significantly different from others, with unique ...
Cached Medicine Technology:Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3Health Strategies Group Introduces Oncology Performance Edge 2Health Strategies Group Introduces Oncology Performance Edge 3
(Date:7/31/2014)... United Theological Seminary is pleased to welcome two ... Peter J. Bellini. Both began their teaching duties on ... Director of Non-Degree Programs, Mark Abbott, who begins his ... Assistant Professor of New Testament, received a Ph.D. from ... Temple Judaism, and Greek courses. His research interests are ...
(Date:7/31/2014)... July 31, 2014 Cosmetic Town is ... Plastic Surgeons to consumers considering cosmetic treatments. The ... peers whose goal is to educate prospective patients on ... selected through a validated referral system that helps patients ... best in their respective fields. , Cosmetic Town ...
(Date:7/31/2014)... The VitaSleep FDA cleared anti-snoring ... provide an easier breathing capacity by slightly adjusting the ... people can breathe easier and helps reduce or even ... that it can meet the needs of each individual ... shared by actual customer reviews. Johathan R. from ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... (LMS) which continues to help healthcare agencies to ... help companies and agencies meet their accreditation ... with competency based training. , Healthcare administrators ... a few clicks of the mouse. Courses can ...
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. S. Ct., ... made the determination that a purchaser of tangible goods in ... unable to prove during an audit that sales tax ... of Appeals decision on whether a purchaser bears the burden ... from Michigan sellers. The Court states “in order to be ...
Breaking Medicine News(10 mins):Health News:Growing Seminary Welcomes New Faculty 2Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3
... group of scientists, led by mathematicians, has taken on ... responses. Their work will radically improve our understanding of ... disciplines working on it to have a common reference ... and Biological Sciences Research Council (BBSRC), will investigate how ...
... Researchers have identified which sites and cell types ... avian influenza viruses, providing valuable insights into the pathogenesis ... et al, Human and avian influenza viruses target different ... other mammals, appears in the October issue of The ...
... Grants Initiative to Support Hundreds of Research Projects ... Involving Scientists Around the World, ... Melinda,Gates Foundation announced today that it is committing $100 million ... support,innovative global health research. The initiative,s goal is to encourage,scientists ...
... Oct. 9 Medical Simulation Corporation (MSC) ... with the Methodist DeBakey Heart,Center in Houston ... help Methodist cardiologists and surgeons improve patient,safety ... update surgical and,interventional skills in a simulated, ...
... Available at ... PhillyHealthInfo.org, PHILADELPHIA, Oct. 9 PhillyHealthInfo is the ... Chester,Delaware, and Montgomery counties. Go to http://www.PhillyHealthInfo.org ,for this season,s flu ... Where to go for free or low cost flu shots. -- ...
... Experiences and sanofi-aventis, Goal to be Part of ... Among Stakeholders, LITTLE ROCK, Ark., Oct. 9 ... at the Collaborative Practice Summit (CPS) hosted by the ... in Uncasville,Conn. CPS brought together a focused group ...
Cached Medicine News:Health News:Mathematicians help unlock secrets of the immune system 2Health News:Influenza: Insights into cell specificity of human vs. avian viruses 2Health News:Gates Foundation Launches $100 Million Initiative to Spur Innovation in Global Health Research 2Health News:Gates Foundation Launches $100 Million Initiative to Spur Innovation in Global Health Research 3Health News:Medical Simulation Corporation Announces Partnership with Methodist DeBakey Heart Center in Houston 2Health News:Sanofi-aventis US Chairman Tim Rothwell Addresses CMSA's Collaborative Practice Summit 2Health News:Sanofi-aventis US Chairman Tim Rothwell Addresses CMSA's Collaborative Practice Summit 3Health News:Sanofi-aventis US Chairman Tim Rothwell Addresses CMSA's Collaborative Practice Summit 4
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: